vTv Therapeutics Randomizes First Participant in Cadisegliatin Phase 2a Trial
vTv Therapeutics said the first participant has been randomized in its Phase 2a study of cadisegliatin for type 1 diabetes.
vTv Therapeutics said the first participant has been randomized in its Phase 2a study of cadisegliatin for type 1 diabetes.